The Feelings of Hubei Audit
Release time:
2021-01-04
Hubei Audit Feelings
Some time ago, I received an audit assignment, and Jin Jinlin from the QA Management Section went to Hubei to audit two suppliers. According to the production plan of the workshop, we have arranged the schedule for December 14-18.
At the first supplier, we examined the case of a partially PTFE-coated halogenated butyl rubber stopper (G20-D1c bromide) for freeze-dried injection. The company completed the site relocation in the first half of this year. We first checked the production site and QC laboratory, and then checked the relevant documents, changes and deviations and related production records. The new factory has invested more than 300 million yuan in the production of rubber plugs, installed fully automated mechanical production equipment, and became the first person to "eat crabs" in the rubber plug industry in the country. According to reports, after the automation of the factory, the production capacity will be expanded while the personnel will be halved.
We also saw at the scene that the operators only did some auxiliary work, realizing the whole process of electronic labeling, location, handover and circulation, and finally the finished products were put into storage, greatly reducing the deviation caused by human beings. The factory now has 8 production lines to realize automatic production, and then a total of 17 production lines will be gradually realized. After watching the production site, I have a certain understanding of the entire life cycle of the rubber plug, filling the gap in the knowledge of the use of the rubber plug in the work. This company gave me the deepest feeling that the first person to "eat crabs" has both risks and opportunities. Reflect on yourself, in the future work, but also through a variety of learning, break the routine, looking for breakthroughs, improve the quality of work.
The second supplier, we inspected the relevant situation of taurine, and the audit process also looked at the production site first, then the relevant documents, etc. This factory only produces one product of taurine. We checked the whole cycle site from the initial material receipt to the final finished product packaging storage according to the production sequence. Walking into the synthetic production plant, the first thing you feel is the visual impact. Different material storage tanks and pipes are painted with different colors, and the area is clearly divided, giving people a feeling of simplifying complexity. The materials in the whole production process are transferred through the equipment pipeline, which reduces the dust production and the environment in the whole production area is clean and tidy. When looking at the deviation record, we found that one deviation occurred in the outer package. After the production on duty, when counting the ties used for tying the mouth, we found that one was missing, and the deviation was investigated around the number of ties used. As the saying goes, production is no small matter, which is probably the case.
When we were about to leave after the audit, we heard about something that had just happened in the production plant, which impressed us. The security officer of the factory ran into a supplier in the factory and asked him, "Do you have a cigarette?" The supplier replied "Yes" and took the cigarette out. The supplier was fined 1000 yuan for a casual question and answer and a subconscious action. The reason is that the production plant not only can not smoke, smoke can not be carried in. This shows us that the manufacturer attaches great importance to safety, not only in the system, but also in action to let everyone remember the safety rules and abide by them.
A trip to the supplier audit, let me see the application of advanced technology in production, but also feel the enterprise's meticulous safety work. (Shi Zhongyuan)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page